Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
N-alpha-acetyltransferase 30 (NAA30) is the catalytic subunit of the NatC N-terminal acetyltransferase complex, an enzyme that co-translationally acetylates the N-termini of numerous eukaryotic proteins (especially those beginning with methionine followed by hydrophobic or amphipathic residues). NAA30’s activity stabilizes substrate proteins, protects them from degradation, and is required for correct mitochondrial function, organelle targeting, and cell viability. Loss or overexpression of NAA30 influences cancer cell growth and survival, and genetic variants are implicated in developmental syndromes and mitochondrial disease. NatC complexes are evolutionarily conserved and crucial for acetylating specific protein subsets across eukaryotes.
Inhibition of protein N-terminal acetylation, which has the potential to disrupt mitochondrial function, cell proliferation, and cancer cell viability by interfering with acetylation of substrate proteins, leading to increased protein degradation and altered organelle function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on N-alpha-acetyltransferase 30, NatC catalytic subunit (NAA30).